BG63940B1 - Бифенилсулфонамидни инхибитори на металопротеиназата на матрикса - Google Patents

Бифенилсулфонамидни инхибитори на металопротеиназата на матрикса Download PDF

Info

Publication number
BG63940B1
BG63940B1 BG102918A BG10291898A BG63940B1 BG 63940 B1 BG63940 B1 BG 63940B1 BG 102918 A BG102918 A BG 102918A BG 10291898 A BG10291898 A BG 10291898A BG 63940 B1 BG63940 B1 BG 63940B1
Authority
BG
Bulgaria
Prior art keywords
biphenyl
sulfonylamino
methyl
butyric acid
alkyl
Prior art date
Application number
BG102918A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG102918A (en
Inventor
Patrick O'brien
Drago SLISKOVIC
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Publication of BG102918A publication Critical patent/BG102918A/xx
Publication of BG63940B1 publication Critical patent/BG63940B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/42—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
BG102918A 1996-05-17 1998-11-12 Бифенилсулфонамидни инхибитори на металопротеиназата на матрикса BG63940B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1746096P 1996-05-17 1996-05-17
PCT/US1997/006801 WO1997044315A1 (fr) 1996-05-17 1997-04-24 Inhibiteurs de metalloproteinase matricielle de biphenylsulfonamide

Publications (2)

Publication Number Publication Date
BG102918A BG102918A (en) 1999-09-30
BG63940B1 true BG63940B1 (bg) 2003-07-31

Family

ID=21782716

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102918A BG63940B1 (bg) 1996-05-17 1998-11-12 Бифенилсулфонамидни инхибитори на металопротеиназата на матрикса

Country Status (23)

Country Link
EP (1) EP0901466B1 (fr)
JP (1) JP2000511175A (fr)
KR (1) KR20000011095A (fr)
CN (1) CN1077885C (fr)
AT (1) ATE207891T1 (fr)
BG (1) BG63940B1 (fr)
BR (1) BR9710841A (fr)
CA (1) CA2253342A1 (fr)
CZ (1) CZ294063B6 (fr)
DE (1) DE69707865T2 (fr)
DK (1) DK0901466T3 (fr)
EA (1) EA001561B1 (fr)
EE (1) EE03965B1 (fr)
ES (1) ES2167733T3 (fr)
HK (1) HK1019585A1 (fr)
IL (1) IL126832A0 (fr)
NO (1) NO312510B1 (fr)
NZ (1) NZ332711A (fr)
PL (1) PL186416B1 (fr)
PT (1) PT901466E (fr)
SK (1) SK282863B6 (fr)
WO (1) WO1997044315A1 (fr)
ZA (1) ZA974223B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU690703B2 (en) * 1994-06-22 1998-04-30 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
US6124333A (en) * 1995-06-22 2000-09-26 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
KR20000057444A (ko) * 1996-12-09 2000-09-15 로즈 암스트롱, 크리스틴 에이. 트러트웨인 심기능부전 및 심실확장의 치료 및 예방 방법
EP1366765A1 (fr) * 1996-12-17 2003-12-03 Warner-Lambert Company Llc Utilisation d'inhibiteurs de métalloproteinase matricielle dans le traitement de maladies neurologiques et la cicatrisation des blessures
EP0946166B1 (fr) 1996-12-17 2004-02-18 Warner-Lambert Company LLC Utilisation d'inhibiteurs de metalloproteinase matricielle dans le traitement de la cicatrisation des blessures
GB9706255D0 (en) 1997-03-26 1997-05-14 Smithkline Beecham Plc Novel compounds
DE19719621A1 (de) * 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarbonsäuren
EP1398027B1 (fr) * 1997-07-22 2007-01-10 Shionogi & Co., Ltd. Utilisation d' inhibiteurs de la métalloprotéase matricielle pour le traitement ou prevention de la glomerulopathie
EP1047450B1 (fr) * 1997-12-23 2002-10-02 Warner-Lambert Company Combinaisons d'inhibiteurs de l'enzyme de conversion de l'angiotensine et d'inhibiteurs de l'enzyme metalloprotease matricielle
HUP0101176A3 (en) * 1998-02-04 2002-06-28 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases, process for their preparation and pharmaceutical compositions containing them
US6410580B1 (en) 1998-02-04 2002-06-25 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
WO1999047138A1 (fr) * 1998-03-17 1999-09-23 Warner-Lambert Company Associations statine-inhibiteur de metalloprotease matricielle
EP0967201A1 (fr) * 1998-05-20 1999-12-29 Roche Diagnostics GmbH Compositions pharmaceutiques contenant des sulphonamides comme inhibiteurs des métalloprotéinases matricielles
BR9912085A (pt) * 1998-07-16 2001-04-10 Aventis Pharma Gmbh Derivados de ácido fosfìnico e ácido fosfÈnico como medicamentos
CZ2001126A3 (cs) * 1998-07-21 2002-01-16 Warner-Lambert Company Společné účinky ACAT a MMP inhibitorů při léčbě aterosklerotických lézí
DE19851184A1 (de) 1998-11-06 2000-05-11 Aventis Pharma Gmbh N-Arylsulfonyl-aminosäure-omega-amide
CN1347411A (zh) * 1999-04-19 2002-05-01 盐野义制药株式会社 含有噁二唑环的磺酰胺衍生物
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
PL211888B1 (pl) 1999-11-26 2012-07-31 Shionogi & Co Związek będący antagonistą NPY Y5 oraz kompozycja farmaceutyczna zawierająca taki związek
CN1273456C (zh) * 2000-09-29 2006-09-06 盐野义制药株式会社 噻唑和噁唑衍生物
GB0103303D0 (en) 2001-02-09 2001-03-28 Novartis Ag Organic compounds
MXPA01013326A (es) * 2001-02-14 2002-08-26 Warner Lambert Co Bifenil sulfonamidas utiles como inhibisdores de metaloproteinasa de matriz.
WO2003035610A1 (fr) * 2001-10-26 2003-05-01 Shionogi & Co., Ltd. Derive de sulfonamide a effet inhibiteur sur les mmp
GB0314488D0 (en) * 2003-06-20 2003-07-23 Glaxo Group Ltd Therapeutically useful compounds
EP1689716A1 (fr) * 2003-12-04 2006-08-16 Wyeth Sulfonamides de biaryle et procedes d'utilisation
PL1735274T3 (pl) 2004-03-22 2010-05-31 Southern Res Inst Niepeptydowe inhibitory metaloproteinaz macierzy zewnątrzkomórkowej
CN101279956B (zh) * 2008-04-25 2011-06-15 南昌大学 一种基质金属蛋白酶抑制剂及合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
AU690703B2 (en) * 1994-06-22 1998-04-30 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors

Also Published As

Publication number Publication date
CZ294063B6 (cs) 2004-09-15
DK0901466T3 (da) 2002-02-18
HK1019585A1 (en) 2000-02-18
AU713286B2 (en) 1999-11-25
EE9800397A (et) 1999-06-15
NO985326L (no) 1999-01-14
EE03965B1 (et) 2003-02-17
PL186416B1 (pl) 2004-01-30
BR9710841A (pt) 1999-08-17
AU2680397A (en) 1997-12-09
ES2167733T3 (es) 2002-05-16
CN1077885C (zh) 2002-01-16
EP0901466A1 (fr) 1999-03-17
CA2253342A1 (fr) 1997-11-27
NO312510B1 (no) 2002-05-21
EP0901466B1 (fr) 2001-10-31
IL126832A0 (en) 1999-08-17
WO1997044315A1 (fr) 1997-11-27
PL329929A1 (en) 1999-04-26
BG102918A (en) 1999-09-30
SK282863B6 (sk) 2002-12-03
EA199800988A1 (ru) 1999-04-29
KR20000011095A (ko) 2000-02-25
CN1219166A (zh) 1999-06-09
JP2000511175A (ja) 2000-08-29
NO985326D0 (no) 1998-11-16
PT901466E (pt) 2002-04-29
DE69707865D1 (de) 2001-12-06
SK157798A3 (en) 1999-04-13
ZA974223B (en) 1997-12-10
ATE207891T1 (de) 2001-11-15
DE69707865T2 (de) 2002-05-02
CZ366898A3 (cs) 1999-02-17
NZ332711A (en) 2000-06-23
EA001561B1 (ru) 2001-04-23

Similar Documents

Publication Publication Date Title
BG63940B1 (bg) Бифенилсулфонамидни инхибитори на металопротеиназата на матрикса
EP0934267B1 (fr) Acides alpha-amino sulfonyle hydroxamiques en tant qu'inhibiteurs de metalloproteinase de matrice
US8816076B2 (en) Aryl urea derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators
US5756545A (en) Biphenysulfonamide matrix metal alloproteinase inhibitors
US5859061A (en) Bis-sulfonamides hydroxamic acids as MMP inhibitors
US8440684B2 (en) Polycyclic pyrrolidine-2,5-dione derivatives as -formyl peptide receptor like-1 (FPRL-1) receptor modulators
US8846760B2 (en) Dihydronaphthalene and naphthalene derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators
KR19980086847A (ko) 설포닐아미노카복실산
JPH0395154A (ja) ［ジ―ｔｅｒｔ―ブチル（ヒドロキシ）フェニルチオ］置換ヒドロキサム酸誘導体
US4134991A (en) Derivatives of 2-(3-phenyl-2-aminopropionyloxy)-acetic acid
FR2707638A1 (fr) Nouveaux dérivés d'amino-acides, leurs procédés de préparation et leur application thérapeutique.
JP2003505367A (ja) マトリックスメタロプロテイナーゼ阻害剤としての３−アリールスルホニル−２−（置換メチル）プロパン酸誘導体
JP2000516607A (ja) 酪酸マトリックスメタロプロテイナーゼ阻害剤
JP2003321424A (ja) エステル化合物及びその医薬用途
AU713286C (en) Biphenylsulfonamide matrix metalloproteinase inhibitors
KR101096427B1 (ko) 신규한 4-아릴-4-옥소부탄산 아미드 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물
JP2000508639A (ja) Ｍｍｐおよびｔｎｆ抑制活性を有するペプチジル化合物
MXPA98009083A (en) Metaloproteinase inhibitors with bifenilsulfonam matrix
EP0375557A1 (fr) Dérivés glycines, procédé pour leur préparation et composition pharmaceutique les contenant